Several recent studies have shown the feasibility of detecting ESR1 mutations in circulating tumour DNA (ctDNA) and that the mutation status in plasma DNA can more accurately reflect the extent of disease heterogeneity than the analysis of tissue from a single metastatic site18, 19, 20. The gene discussed is ESR1; the disease is neoplasm.